Soleo Health has just announced that they have been provided access to lumasiran by Alnylam Pharmaceuticals. This access will allow the company to administer the treatment to patients diagnosed with a rare condition called primary hyperoxaluria type 1 (PH1). This therapy is the first drug approved by the FDA which lowers urinary oxalate levels in both pediatric and adult patients. Lumasiran is approved for patients as young as 3 months old.
PH1
PH1 is an extremely rare condition caused by an excessive production of oxalate within the liver. This overproduction occurs because one enzyme in the liver responsible for breaking down oxalate isn’t produced at a high enough quantity.
As a result of the buildup of oxalate, urinary stones and kidney stones are extremely common. The more often these stones occur, the higher the risk that patients will experience chronic kidney disease and ultimately, kidney failure.
The lumasiran treatment reduces the production of the oxalate within the liver. This reduction leads to a reduced chance of stone formation, and a reduced risk of a chronic kidney disease diagnosis.
Soleo Health
Soleo Health provides injections of the treatment at Ambulatory Infusion Centers across the United States. All staff (an interdisciplinary team of pharmacists, patient care ambassadors, and nurses) are trained for this specific medication and administration.
Soleo’s history with rare and ultra-rare diseases makes them a perfect choice for administering this therapy. Patients can rest assured that they’re in good hands.
Additionally, through the company’s clinical outcomes program called SoleMetrics, patient data will be collected to improve our understanding of this treatment and how it can improve PH1 patient lives.
You can read more about this treatment and Soleo Health’s role here.
